Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents

British Journal of Ophthalmology

Volumn 95, Issue 8, 2011, Pages 1111-1114

  Good, Travis J ^a   Kimura, Alan E ^b   Mandava, Naresh ^a   Kahook, Malik Y ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b Ophthalmic Technician   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

AGED; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; EXUDATIVE MACULAR DEGENERATION; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; LASER SURGERY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; GLAUCOMA; HUMANS; INCIDENCE; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; KAPLAN-MEIER ESTIMATE; MACULAR DEGENERATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79960648025     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2010.180729     Document Type: Article

References (21)

1. Kvanta A, Algvere PV, Berglin L, et al. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1996;37:1929-34. (Pubitemid 26324159)
2. Shams N, Ianchulev T. Role of vascular endothelial growth factor in ocular angiogenesis. Ophthalmol Clin North Am 2006;19:335-44. (Pubitemid 44279356)
3. Bressler SB. Introduction: understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration. Ophthalmology 2009;116:S1-7.
4. Package insert. Avastin (Bevacizumab). San Francisco: Genentech, 2004.
5. Package insert. Lucentis (Ranibizumab). San Francisco: Genentech, 2006.
6. Zondor SD, Medina PJ. Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann Pharmacother 2004;38:1258-64. (Pubitemid 38802172)
7. Bressler NM. Antiangiogenic approaches to age-related macular degeneration today. Ophthalmology 2009;116:S15-23.
8. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006;26:495-511. (Pubitemid 44620390)
9. Fung AE, Rosenfeld PJ, Reichel E. The International intravitreal bevacizumab safety survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006;90:1344-9. (Pubitemid 44702055)
10. Gordon A, Maximiliano M. Bevacizumab local complications. Ophthalmology 2009;116:2264.e1-3.
11. Jalil A, Fenerty C, Charles S. Intravitreal bevacizumab causing acute glaucoma: an unreported complication. Eye 2007;21:1541.
12. Zheng Q, Mayer H, Adelman RA. Persistent ocular hypertension following multiple intravitreal Anti-VEGF Injections for AMD. Invest Ophthalmol Vis Sci 2009;50:E-Abstract 959.
13. Bakri SJ, McCannel CA, Edwards AO, et al. Persistent ocular hypertension following intravitrea ranibizumab. Graefes Arch Clin Exp Ophthalmol 2008;246:955-8.
14. Kahook MY, Kimura AE, Wong LS, et al. Sustained elevation of intraocular pressure associated with intravitreal bevacizumab injections. Ophthalmic Surg Laser Imaging 2009;40:293-5.
15. Carver J, Bouska C, Corey R. Avastin and risk of glaucoma [abstract]. New York: Retina Congress, 2009.
16. Drance SM. The significance of the diurnal tension variations in normal and glaucomatous eyes. Arch Ophthalmol 1960;64:494-501.
17. Jager JD, Aiello LP, Patel SC, et al. Risk of intravitreous injection: a comprehensive review. Retina 2004;24:676-98. (Pubitemid 39391758)
18. Ladas JG, Yu F, Davis JL, et al. Relationship between aqueous humor protein level and outflow facility in patients with uveitis. Invest Ophthalmol Vis Sci 2001;42:2584-8. (Pubitemid 32954867)
19. Georgopoulos M, Polak K, Prager F, et al. Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin). Br J Ophthalmol 2009;93:457-62.
20. Kahook MY, Liu L, Ruzycki P, et al. High-molecular-weight aggregates in repackaged bevacizumab. Retina 2010;30:887-92.
21. Rosenberg AS. Effects of protein aggregates: an immunologic perspective. AAPS J 2006;8:E501-7.